Koya Medical’s Compression Therapy System Dayspring Is Designed To Treat Lymphedema And Venous Diseases

Lymphedema a happens when your body’s lymph system is damaged or blocked due to protein rich ...

Koya Medical

Lymphedema happens when your body’s lymph system is damaged or blocked due to protein-rich fluid. This can lead to feelings of pain as well as heaviness, and interfere with your daily activities if left untreated. An estimated 20 million Americans live with this progressive and incurable condition.

Read more: Henkel’s Printed Electronics Solutions Are Propelling Smart Living, Mobility and Hygiene

California-based MedTech company Koya Medical has developed an active compression therapy system Dayspring for the treatment of lymphedema and venous diseases that impact lymphatic flow in lower extremities.

The Dayspring system is the first wearable and mobility-enabled compression system designed with real life in mind. It is the first and only compression therapy option designed to enable movement, mobility, and personalized care that is unavailable with traditional compression therapy. The Dayspring system includes a low-profile active garment made of a soft, breathable mesh using Koya’s proprietary Flexframe technology; a smart, rechargeable, hand-held controller that can be worn on a lanyard; and a mobile app that allows users or their clinicians to program custom treatment options.

Patients treated with Dayspring, the prescription-only medical device, receive standard of care active compression therapy with a mobility-enabling wearable device designed with real-life demands in mind. The Dayspring system includes a low-profile active garment made of a soft, breathable mesh using Koya’s proprietary Flexframe technology; a smart, rechargeable, hand-held controller that can be worn on a lanyard; and a mobile app that allows users or their clinicians to program custom treatment options. Koya previously received FDA clearance for Dayspring for upper extremities in June 2020, according to a press release.

“Lymphedema can be physically and emotionally debilitating for patients, so a daily treatment option that enables mobility and allows them to receive treatment while continuing their daily life activities is a significant breakthrough,” said Andy Doraiswamy, Ph.D., Koya founder, President, and CEO. “We are excited about this new indication and milestone, as well as the addition of three new esteemed executive leaders. Rick, Liesl, and Damian bring a wealth of highly relevant experience building successful medical technology companies and will be invaluable in supporting Koya as it transforms lymphatic and vein care by providing access to our innovative products to patients all over the world.”

Read more: KOB Manufactures Medical Textiles for Smart Applications in Patient Monitoring and Therapy

About Koya Medical

Koya Medical is developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care that is unavailable with traditional compression therapy. The privately held company was founded in 2018 with the mission to transform lymphatic and vein care through innovative patient-centric platforms.

Sam Draper
July 8, 2021

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

FDA Authorizes Tandem’s Interoperable, Automated Insulin Dosing Controller

Tandem Diabetes Care, a San Diego, CA-based insulin delivery and diabetes technology company...

Vitls Wins FDA Clearance For Its Remote Patient Monitoring Platform

Houston, Texas-based Vitls Inc. won FDA 510(k) clearance for its Vitls Platform

Apple Watch Glucose Tracker Reaches Proof-Of-Concept

Apple reached the proof-of-concept stage of noninvasive blood glucose monitoring technology.

Clinical Trial Services Company VeraSci Joins Forces with ActiGraph to Expand Wearables Use in Clinical Trials

VeraSci, a global clinical research company announced it has partnered with ActiGraph, a leading...
Discover more